Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Sells Shares Under 10b5-1 Trading Plan

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 3,231 shares of common stock at $510 per share on March 13, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 3,231 shares of common stock on March 13, 2025.
• The sale was executed at a price of $510 per share.
• The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was established on August 8, 2024.
• Following the transaction, Altshuler directly owns 23,281 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates